Tristel PLC - Cambridgeshire-based maker of infection prevention, contamination control and hygiene products - Announces that it has received three regulatory approvals. In the US, gets first approval from the Environmental Protection Agency for its foam-based disinfectant for surfaces in April 2018. In Canada, Tristel's Duo OPH has been approved by Health Canada as a class 2 medical device and is included in Health Canada's Medical Device License Listing. Duo OPH is a high-level disinfectant intended for use on ophthalmic instruments including ultrasound devices and re-usable tonometers and lenses that contact the cornea. In South Korea, Tristel Duo ULT has now been approved as a high-level disinfectant for ultrasound devices, and with Trio will be sold throughout South Korea by HP&C Ltd.
Paul Swinney, CEO of Tristel commented: "Every regulatory approval we achieve represents an important milestone in our progress, and these three approvals are very significant. The enhanced claim set that we have achieved for Jet now justifies taking the product through state-wide registration in the US and gearing up our manufacturing and distribution partnership with Parker Laboratories.
"The approval of Duo OPH by Health Canada represents our first successful registration of a medical device high-level disinfectant in North America. We are actively pursuing a submission to the US FDA for Duo ULT and we are buoyed by this successful application in Canada. The approval in South Korea increases the visibility of our chlorine dioxide technology in the country and extends our distributor's involvement into more clinical areas within a hospital."
Current stock price: 623.00p
Year-to-date change: up 17%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Tristel (TSTL)